Comprehensive review of safety in Experimental Human Pneumococcal Challenge.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
11
2022
accepted:
29
03
2023
medline:
8
5
2023
pubmed:
4
5
2023
entrez:
4
5
2023
Statut:
epublish
Résumé
Experimental Human Pneumococcal Challenge (EHPC) involves the controlled exposure of adults to a specific antibiotic-sensitive Streptococcus pneumoniae serotype, to induce nasopharyngeal colonisation for the purpose of vaccine research. The aims are to review comprehensively the safety profile of EHPC, explore the association between pneumococcal colonisation and frequency of safety review and describe the medical intervention required to undertake such studies. A single-centre review of all EHPC studies performed 2011-2021. All recorded serious adverse events (SAE) in eligible studies are reported. An unblinded meta-analysis of collated anonymised individual patient data from eligible EHPC studies was undertaken to assess the association between experimental pneumococcal colonisation and the frequency of safety events following inoculation. In 1416 individuals (median age 21, IQR 20-25), 1663 experimental pneumococcal inoculations were performed. No pneumococcal-related SAE have occurred. 214 safety review events were identified with 182 (12.85%) participants presenting with symptoms potentially in keeping with pneumococcal infection, predominantly in pneumococcal colonised individuals (colonised = 96/658, non-colonised = 86/1005, OR 1.81 (95% CI 1.28-2.56, P = <0.001). The majority were mild (pneumococcal group = 72.7% [120/165 reported symptoms], non-pneumococcal = 86.7% [124/143 reported symptoms]). 1.6% (23/1416) required antibiotics for safety. No SAEs were identified directly relating to pneumococcal inoculation. Safety review for symptoms was infrequent but occurred more in experimentally colonised participants. Most symptoms were mild and resolved with conservative management. A small minority required antibiotics, notably those serotype 3 inoculated. Outpatient human pneumococcal challenge can be conducted safely with appropriate levels of safety monitoring procedures in place.
Identifiants
pubmed: 37141259
doi: 10.1371/journal.pone.0284399
pii: PONE-D-22-31116
pmc: PMC10159102
doi:
Substances chimiques
Pneumococcal Vaccines
0
Anti-Bacterial Agents
0
Types de publication
Review
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0284399Informations de copyright
Copyright: © 2023 Robinson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Trials. 2019 Dec 19;20(Suppl 2):704
pubmed: 31852488
Am J Respir Crit Care Med. 2015 Oct 1;192(7):853-8
pubmed: 26114410
PLoS One. 2020 Mar 10;15(3):e0229558
pubmed: 32155176
Pediatr Infect Dis J. 2013 Mar;32(3):227-32
pubmed: 23558321
J Clin Invest. 2019 Jul 30;129(10):4523-4538
pubmed: 31361601
Eur Respir J. 2018 Oct 10;52(4):
pubmed: 30305331
Infect Immun. 2003 Oct;71(10):5724-32
pubmed: 14500493
Am J Respir Crit Care Med. 2021 Mar 1;203(5):604-613
pubmed: 32941735
Wellcome Open Res. 2020 Feb 11;5:25
pubmed: 32399498
Emerg Infect Dis. 2016 Nov;22(11):1996-1999
pubmed: 27767919
Am J Respir Crit Care Med. 2013 Apr 15;187(8):855-64
pubmed: 23370916
Am J Respir Crit Care Med. 2019 May 1;199(9):1160-1163
pubmed: 30758980
Am J Respir Crit Care Med. 2022 Dec 1;206(11):1379-1392
pubmed: 35802840
Sci Rep. 2018 Jul 23;8(1):11030
pubmed: 30038420
Lancet Microbe. 2021 Jul;2(7):e291-e299
pubmed: 35544165
J Exp Med. 2002 Feb 4;195(3):359-65
pubmed: 11828011
Trends Microbiol. 2011 Sep;19(9):464-70
pubmed: 21784641
Wellcome Open Res. 2022 Apr 22;7:140
pubmed: 35505774